BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 35478117)

  • 1. Combined OPCML and AXL Expression as a Prognostic Marker and OPCML Enhances AXL Inhibitor in Cholangiocarcinoma.
    Khamko R; Wasenang W; Daduang J; Settasatian C; Limpaiboon T
    In Vivo; 2022; 36(3):1168-1177. PubMed ID: 35478117
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Khamko R; Daduang J; Settasatian C; Limpaiboon T
    Cancer Genomics Proteomics; 2021; 18(6):771-780. PubMed ID: 34697068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer.
    Antony J; Zanini E; Kelly Z; Tan TZ; Karali E; Alomary M; Jung Y; Nixon K; Cunnea P; Fotopoulou C; Paterson A; Roy-Nawathe S; Mills GB; Huang RY; Thiery JP; Gabra H; Recchi C
    EMBO Rep; 2018 Aug; 19(8):. PubMed ID: 29907679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum cell-free DNA methylation of OPCML and HOXD9 as a biomarker that may aid in differential diagnosis between cholangiocarcinoma and other biliary diseases.
    Wasenang W; Chaiyarit P; Proungvitaya S; Limpaiboon T
    Clin Epigenetics; 2019 Mar; 11(1):39. PubMed ID: 30832707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene expression profiling of cholangiocarcinoma-derived fibroblast reveals alterations related to tumor progression and indicates periostin as a poor prognostic marker.
    Utispan K; Thuwajit P; Abiko Y; Charngkaew K; Paupairoj A; Chau-in S; Thuwajit C
    Mol Cancer; 2010 Jan; 9():13. PubMed ID: 20096135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA methylation level of OPCML and SFRP1: a potential diagnostic biomarker of cholangiocarcinoma.
    Amornpisutt R; Proungvitaya S; Jearanaikoon P; Limpaiboon T
    Tumour Biol; 2015 Jul; 36(7):4973-8. PubMed ID: 25652468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MET‑RON dual inhibitor, BMS‑777607, suppresses cholangiocarcinoma cell growth, and MET‑RON upregulation indicates worse prognosis for intra‑hepatic cholangiocarcinoma patients.
    Cheng CT; Chen YY; Wu RC; Tsai CY; Chiang KC; Yeh TS; Chen MH; Yeh CN
    Oncol Rep; 2018 Sep; 40(3):1411-1421. PubMed ID: 30015968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gankyrin promotes tumor growth and metastasis through activation of IL-6/STAT3 signaling in human cholangiocarcinoma.
    Zheng T; Hong X; Wang J; Pei T; Liang Y; Yin D; Song R; Song X; Lu Z; Qi S; Liu J; Sun B; Xie C; Pan S; Li Y; Luo X; Li S; Fang X; Bhatta N; Jiang H; Liu L
    Hepatology; 2014 Mar; 59(3):935-46. PubMed ID: 24037855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CpG-island methylation study of liver fluke-related cholangiocarcinoma.
    Sriraksa R; Zeller C; El-Bahrawy MA; Dai W; Daduang J; Jearanaikoon P; Chau-In S; Brown R; Limpaiboon T
    Br J Cancer; 2011 Apr; 104(8):1313-8. PubMed ID: 21448164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Axl Inhibitor R428 Enhances TRAIL-Mediated Apoptosis Through Downregulation of c-FLIP and Survivin Expression in Renal Carcinoma.
    Woo SM; Min KJ; Seo SU; Kim S; Kubatka P; Park JW; Kwon TK
    Int J Mol Sci; 2019 Jul; 20(13):. PubMed ID: 31269715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trefoil factors: tumor progression markers and mitogens via EGFR/MAPK activation in cholangiocarcinoma.
    Kosriwong K; Menheniott TR; Giraud AS; Jearanaikoon P; Sripa B; Limpaiboon T
    World J Gastroenterol; 2011 Mar; 17(12):1631-41. PubMed ID: 21472131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Prognostic Role of SOCS3 and A20 in Human Cholangiocarcinoma.
    Wang Y; Wan M; Zhou Q; Wang H; Wang Z; Zhong X; Zhang L; Tai S; Cui Y
    PLoS One; 2015; 10(10):e0141165. PubMed ID: 26485275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy.
    Yothaisong S; Dokduang H; Techasen A; Namwat N; Yongvanit P; Bhudhisawasdi V; Puapairoj A; Riggins GJ; Loilome W
    Tumour Biol; 2013 Dec; 34(6):3637-48. PubMed ID: 23832540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Annexin A1 Is a Potential Prognostic Marker for, and Enhances the Metastasis of, Cholangiocarcinoma.
    Kotepui KU; Obchoei S; Vaeteewoottacharn K; Okada S; Wongkham S; Sawanyawisuth K
    Asian Pac J Cancer Prev; 2022 Feb; 23(2):715-721. PubMed ID: 35225485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer.
    Holland SJ; Pan A; Franci C; Hu Y; Chang B; Li W; Duan M; Torneros A; Yu J; Heckrodt TJ; Zhang J; Ding P; Apatira A; Chua J; Brandt R; Pine P; Goff D; Singh R; Payan DG; Hitoshi Y
    Cancer Res; 2010 Feb; 70(4):1544-54. PubMed ID: 20145120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma.
    Ewald F; Grabinski N; Grottke A; Windhorst S; Nörz D; Carstensen L; Staufer K; Hofmann BT; Diehl F; David K; Schumacher U; Nashan B; Jücker M
    Int J Cancer; 2013 Nov; 133(9):2065-76. PubMed ID: 23588885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Curcumin suppresses proliferation and induces apoptosis in human biliary cancer cells through modulation of multiple cell signaling pathways.
    Prakobwong S; Gupta SC; Kim JH; Sung B; Pinlaor P; Hiraku Y; Wongkham S; Sripa B; Pinlaor S; Aggarwal BB
    Carcinogenesis; 2011 Sep; 32(9):1372-80. PubMed ID: 21325634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Down-regulated expression of OPCML predicts an unfavorable prognosis and promotes disease progression in human gastric cancer.
    Xing X; Cai W; Ma S; Wang Y; Shi H; Li M; Jiao J; Yang Y; Liu L; Zhang X; Chen M
    BMC Cancer; 2017 Apr; 17(1):268. PubMed ID: 28407749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. YKL-40/chitinase-3-like protein 1 is associated with poor prognosis and promotes cell growth and migration of cholangiocarcinoma.
    Thongsom S; Chaocharoen W; Silsirivanit A; Wongkham S; Sripa B; Choe H; Suginta W; Talabnin C
    Tumour Biol; 2016 Jul; 37(7):9451-63. PubMed ID: 26781979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic targeting of ARID1A and PI3K/AKT pathway alterations in cholangiocarcinoma.
    Tessiri S; Techasen A; Kongpetch S; Namjan A; Loilome W; Chan-On W; Thanan R; Jusakul A
    PeerJ; 2022; 10():e12750. PubMed ID: 35070505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.